Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is needed to improve holistic patient care, according to a new editorial.
SPAC Ashington Innovation plans to acquire dormant biotech Celixir and lead heart failure program for $172M
London-based SPAC Ashington Innovation is planning to acquire dormant, UK-based biotech Celixir for $172 million (£135 million) in an all-share transaction, taking over its lead